The Pennsylvania Society of Oncology and Hematology represents more than 200 physicians and other health care professionals who care for cancer patients. The Society is a non-profit corporation devoted to the improvement of hematologic and oncologic care of patients.

Membership in the Society is open to physicians, allied health professionals, and institutions with a demonstrated interest and involvement in the care of patients with hematologic and oncologic disorders. It is also open to residents and fellows who are actively enrolled in a full-time residency program in hematology or oncology in Pennsylvania or who are in an appropriate fellowship program. Corporate entities involved in the care and treatment of cancer patients may also become members.

The site provides resources for cancer patients, including a searchable database of Society members for those individuals seeking an oncologist, hematologist, surgical oncologist, or radiation oncologist.

The Pennsylvania Society of Oncology and Hematology is grateful to our Corporate Sponsors, whose donations help us fulfill our mission.

Dr. Moshe Chasky, Secretary/Treasurer of the PSOH Board, speaks about why he joined PSOH, and the value and friendships from colleagues he has gained from his membership.

ASCO and NCI Patient Information Wallet Card

Wallet Card Helps Doctors and Patients Stay Connected During Disasters

The American Society of Clinical Oncology (ASCO) and the National Cancer Institute (NCI) have developed a tool that we hope will be helpful to oncologists and people with cancer in the event of a national or natural disaster, when patients may not be able to access their medical team for care.

ASCO and NCI have developed and tested with physicians and other medical staff a card that patients can carry in their wallets that will guide them to ASCO's patient information Web site (www.cancer.net) and NCI's Cancer Information Service (1-800-4-CANCER) if they are displaced from their homes due to a disaster situation. Download and print out the card.

The card includes information on how to access ASCO and NCI information tools. It also includes space on the back, where medical staff can include brief information about the patient's care in case the patient needs to be treated by a doctor who is unfamiliar with his or her diagnosis or treatment.

For more information click here.

2019 PA Cancer Conference Registration is Now Open

Registration is now open for the 2019 Pennsylvania Cancer Conference, the Path Forward...Today, Tomorrow and Beyond, being held April 10-11, 2019, at the Harrisburg University. Attendees will be able to participate in multi-track panel discussions on key cancer issues.

The keynote speaker is Harold P. Freeman, MD, of the Harold P. Freeman Patient Navigation Institute in New York City. Registration is free but space is limited.

Visit http://summits.harrisburg.edu/cancer-summit/schedule/ for additional information and to register.

Array BioPharma’s Encorafenib & Binimetinib Approved by FDA

As a member of PSOH we are sharing the following information from our Corporate Member, Array BioPharma, Inc’s recent FDA approval.

Array BioPharma Inc., is pleased to announce that the U.S. Food and Drug Administration has approved encorafenib (BRAFTOVI™) capsules, and binimetinib (MEKTOVIĀ®) tablets, as an oral combination therapy for patients with unresectable or metastatic melanoma with a BRAF V600E/K mutation as detected by an FDA-approved test. BRAFTOVI is not indicated for the treatment of patients with wild-type BRAF melanoma.

Click here to read the full press release

Full Prescribing information is available at: www.braftovimektovi.com

For additional information, please contact Bentley Boivin, Access Account Director at Array BioPharma at 518-441-8080 or email Bentley.boivin@arraybiopharma.com.


Our Corporate Members

Pennsylvania Society of Oncology and Hematology
777 East Park Drive, PO Box 8820
Harrisburg, PA 17105-8820
(717) 558-7750, ext. 1587

This website brought to you by:

Website design by Sister Webs Design Studio, where 5% of profits are donated to women's cancer funds

Our Corporate Members